An efficacy equivalent of 1.0 times (or even less) would still be statistically highly successful because the ratio is based on using 10% of the standard HCQ dose.
You’ve missed the entire point which is to achieve efficacy using a substantively lower dose of HCQ.
Imagine you’re a rheumatoid arthritis sufferer with positive results from HCQ, however you experience ocular side affects which cease to be present at lower doses of HCQ while maintaining treatment efficacy. Guess which drug the Doctor prescribes and ultimately receives PBS admission?
This is how drug development works and these results are off the charts.
IHL Price at posting:
21.5¢ Sentiment: Buy Disclosure: Held
